Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice

Cancer Prevention Research

Volumn 5, Issue 7, 2012, Pages 963-972

  Li, Guangxun ^c   Wang, Hong ^c   Liu, Anna B ^a   Cheung, Connie ^a   Reuhl, Kenneth R ^a   Bosland, Maarten C ^b   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; ANDROGEN RECEPTOR; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; DNA METHYLTRANSFERASE 1; GLUTATHIONE TRANSFERASE P1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P63; UVOMORULIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MODEL; CANCER PREVENTION; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; DIETARY INTAKE; DNA METHYLATION; FEMALE; GENE SILENCING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOGENESIS; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; CADHERINS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 CYP1A2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 84866452965     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0023     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Norrish AE, Ferguson LR, Knize MG, Felton JS, Sharpe SJ, Jackson RT. Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 1999;91:2038-44.
3. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001;12:557-67. (Pubitemid 32735128)
4. Rohrmann S, Hermann S, Linseisen J. Heterocyclic aromatic amine intake increases colorectal adenoma risk: findings from a prospective European cohort study. Am J Clin Nutr 2009;89:1418-24.
5. Friesen MD, Kaderlik K, Lin D, Garren L, Bartsch H, Lang NP, et al. Analysis of DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rat and human tissues by alkaline hydrolysis and gas chromatography/electron capture mass spectrometry: validation by comparison with 32P-postlabeling. Chem Res Toxicol 1994;7:733-9. (Pubitemid 24370229)
6. Tang D, Liu JJ, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, et al. Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev 2007;16:803-8. (Pubitemid 46650585)
7. El-Zein R, Etzel CJ, Lopez MS, Gu Y, Spitz MR, Strom SS. Human sensitivity to PhIP: a novel marker for prostate cancer risk. Mutat Res 2006;601:1-10. (Pubitemid 44528592)
8. Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RB, et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005;65:11779-84. (Pubitemid 41821740)
9. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4-66.
10. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45. (Pubitemid 40467547)
11. Shirai T, Cui L, Takahashi S, Futakuchi M, Asamoto M, Kato K, et al. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett 1999;143:217-21. (Pubitemid 29392960)
12. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 1997;57:195-8. (Pubitemid 27036591)
13. Hasegawa R, Sano M, Tamano S, Imaida K, Shirai T, Nagao M, et al. Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP) carcinogenicity in rats. Carcinogenesis 1993;14: 2553-7. (Pubitemid 24016595)
14. Adamson RH, Snyderwine EG, Thorgeirsson UP, Schut HA, Turesky RJ, Thorgeirsson SS, et al. Metabolic processing and carcinogenicity of heterocyclic amines in nonhuman primates. Princess Takamatsu Symp 1990;21:289-301.
15. Hirose M, Yamaguchi T, Lin C, Kimoto N, Futakuchi M, Kono T, et al. Effects of arctiin on PhIP-induced mammary, colon and pancreatic carcinogenesis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats. Cancer Lett 2000;155:79 - 88.
16. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 2006;8:708-15. (Pubitemid 44465522)
17. Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 2007;67:1378-84.
18. Rao CV, Rivenson A, Zang E, Steele V, Kelloff G, Reddy BS. Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz. Cancer Res 1996;56:3395-8. (Pubitemid 26251625)
19. Esumi H, Ohgaki H, Kohzen E, Takayama S, Sugimura T. Induction of lymphoma in CDF1 mice by the food mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine. Jpn J Cancer Res 1989; 80:1176-8. (Pubitemid 20050985)
20. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, et al. Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 2005;18:1471-8. (Pubitemid 41361721)
21. Dragin N, Uno S, Wang B, Dalton TP, Nebert DW. Generation of 'humanized' hCYP1A1-1A2-Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun 2007;359:635-42. (Pubitemid 46898998)
22. Cheung C, Loy S, Li GX, Liu AB, Yang CS. Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine and dextran sodium sulfate. Carcinogenesis 2011;32:233-9.
23. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-in flammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9:419-26.
24. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
25. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 2007;25:398-400. (Pubitemid 47362760)
26. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005;65:6773-9. (Pubitemid 41060715)
27. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176:1012-6. (Pubitemid 44142579)
28. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-91. (Pubitemid 44454708)
29. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815-26. (Pubitemid 33062524)
30. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
31. Newmark HL, Yang K, Lipkin M, Kopelovich L, Liu Y, Fan K, et al. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis 2001;22:1871-5. (Pubitemid 33064854)
32. Park JH, Walls JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161:727-35. (Pubitemid 36142181)
33. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305. (Pubitemid 38339483)
34. Ahmad I, Sansom OJ, Leung HY. Advances in mouse models of prostate cancer. Expert Rev Mol Med 2008;10:e16.
35. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9. (Pubitemid 38524696)
36. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
37. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
38. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997;57:3189-93. (Pubitemid 27351734)
39. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 1994;7:835-41.
40. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. Hypermethylation of the human glutathione S -transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163:923-33. (Pubitemid 37040128)
41. Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, et al. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 2001;61:103-9. (Pubitemid 32095707)
42. Meiers I, Shanks JH, Bostwick DG. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review. Pathology 2007;39:299-304. (Pubitemid 46897603)
43. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009;150:3991-4002.
44. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010;17:245-55.
45. Hammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar FF. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 1997;18:851-4. (Pubitemid 28132477)
46. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis 1999;20:353-68. (Pubitemid 29112620)
47. Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a perspective on transgenic mouse models. Cancer Metastasis Rev 2010;29:123-42.
48. Thomas JA II, Freedland SJ. Obesity and prostate cancer: collateral damage in the battle of the bulge. Front Biosci (Schol Ed) 2011;3:594-605.
49. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 2011;4:486-501.
50. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60. (Pubitemid 46211548)